Flavio G. Vincenti

MD

Kidney and pancreas transplant specialist

Dr. Flavio Vincenti is a specialist in kidney and pancreas transplantation. He came to UCSF Medical Center in 1975 for a fellowship in transplant nephrology and was appointed a member of the kidney transplant team.

In 1978, Vincenti co-authored an article in the New England Journal of Medicine on the role of blood transfusions in improving kidney transplants. He also wrote a series of articles on the complications of transplants and has been a leading investigator and writer on the use of anti–interleukin 2 receptor monoclonal antibodies, used to reduce the chance of organ rejection. In addition, he is a proponent of minimizing immunosuppressive drugs after transplants.

Vincenti is a member of many professional organizations, including the Transplantation Society, American Society of Nephrology, American Society of Transplantation and International Society of Nephrology. He is a co-leader of the Immune Tolerance Network's kidney section. In addition, he is on the editorial boards of Graft and the American Journal of Kidney Diseases.

  • Education

    American University Medical Center of Beirut, 1971

  • Residencies

    American University Medical Center of Beirut, Internal Medicine

  • Fellowships

    Emory University Hospital, Nephrology, 1975

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Nephrology, American Board of Internal Medicine

  • Academic Title

    Professor

  • Languages

    Arabic

    French

    Italian

Conditions I specialize in

Clinics I work with

View map

Kidney Transplant Center

400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143

(415) 353-1551
M-F, 8 a.m. - 5 p.m.

Pancreas Transplant Services

400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143

(415) 353-1551
M-F, 8 a.m. - 5 p.m.

Selected research

Decorative Caduceus

Treg Modulation With CD28 and IL-6 Receptor Antagonists

Definitions: Acute T cell Mediated Rejection: Biopsy proven rejection defined by histologic evidence of a Banff grade of ≥1A and clinical treatment for acute rejection. Acute Antibody Mediated Rejection: Diffusely positive immun...

Recruiting

Contact me

Providers on my team

Share